Articles On Bionomics (ASX:BNO)

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

ADELAIDE, Australia, Jan. 12, 2022 /PRNewswire/ — Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually...

Bionomics Limited (BNO) announces the issuance of 243,300 American Depositary Shares (ADSs), to exercise the option connected with a previously announced IPO The ADSs each represent 180 ordinary shares of Bionomics and were sold at a publi...

US stocks fell hard as Fed outlines rate cut plan There were more investor jitters over interest rates overnight, as minutes from the Fed’s December meeting showed that policymakers had outlined plans to lift rates sooner than expected, and...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The ASX started the week lower as a result of a drop in the energy and financial sectors. Energy shares fell by over 3%, as surging cases of the Omicron variant raised fears that new restrictions may hit fuel demand. Financials meanwhile we...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

ADELAIDE, Australia, Dec. 16, 2021 /PRNewswire/ — Bionomics Limited (Bionomics or Company), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering in the United States (the Offering) of 1,622,...

While US markets rose after the Fed outlined plans to gradually withdraw stimulus, our markets did not follow suit even amidst a sea of deals. Leading the charge today was IGO (ASX:IGO) which after months of negotiations looks to have inked...

The ASX 200 Health Index (XHJ) is trading higher by 0.27% at the time of writing, compared to the broader index which is down by 0.40%. Fertility company Virtus Health (ASX:VRT) is being pursued by a takeover offer from BGH Capital. BGH, wh...

US stocks fall ahead of Fed meeting On Wall Street, all three major benchmarks finished lower ahead of the final US Fed meeting of the year, to be held today (US time). After last week’s best weekly gain since February, the S&P 500 fell...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

The ASX closed the fourth last week before Christmas up for the day, but once again down for the week. The ASX 200 closed 0.22% higher at 7,241 but down 0.52% for the week – the fourth straight week it has finished down. Energy was the top...

Bionomics (ASX:BNO) has announced that the US FDA has granted Fast Track designation to the BNC210 development program for the acute treatment of Social Anxiety Disorder and other anxiety-related disorders.

ADELAIDE, Australia, Dec. 1, 2021 /PRNewswire/ – Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has grante...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Benchmark US indices closed mixed on Tuesday, November 23, as technology stocks declined, and bond yields rose a day after Biden re-nominated Gerome Powell as Fed chair. The S&P 500 climbed 0.17% to 4,690.70. The Dow Jones was up 0.55%...

ADELAIDE, Australia, Nov. 23, 2021 /PRNewswire/ — Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, today announced the public filing of a registration statement on Form F-1 with th...

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is up by 0.30%. Immutep Limited (ASX:IMM) has has successfully completed patient recruitment for the Phase II TACTI-002 study of LAG-3...

Bionomics (ASX:BNO) has received US FDA clearance to proceed with evaluating its lead clinical compound, BNC210, for the acute treatment of Social Anxiety Disorder in a Phase 2 clinical trial.

U.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial, the PREVAIL Study The PREVAIL Study remains on target to initiate by end of 2021 and is expected...

The ASX started flat and closed flat as local markets struggled for direction in Thursday trade. By flat we mean almost literally, as the ASX 200 closed 0.02% higher on the day. Modest gains in financials and tech stocks were offset by the...

It was a fairly turbulent night on global markets, but the ASX 200 put in a fairly solid day of trade on Thursday to snap a two-day losing streak. Risk-on sentiment held sway as the microcap Emerging Companies index rose more than 1%, while...

The broad Australian indices have started the day off in the red as the market resets from a number of stirrups this week. The S&P/ASX 200 index (ASX: XJO) has clipped 0.37% lower today and sits at 7,343 points, whereas the S&P/AS...

Clinical-stage biopharmaceutical company Bionomics (ASX:BNO) has announced it will proceed with evaluating its lead clinical compound, BNC210, for the treatment of acute Social Anxiety Disorder.

Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder Phase 2 clinical trial on target to start by end of 2021 and expected to read out to...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It was another positive close for the Australian bourse today with energy the standout sector. The ASX 200 closed 0.17% higher at 7,503 points while the ASX Emerging Companies Index gained 1.1% to close at 2,262 points. Leading the charge w...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Bionomics (ASX:BNO) has announced that it plans to conduct a registered initial public offering of shares in the US and a listing on Nasdaq.

ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offerin...

The S&P/ASX200 closed up Monday, gaining 98.80 points or 1.34% to 7,491.40 and setting a new 100-day high. Over the last five days, the index has gained 1.31% and is currently 0.20% off of its 52-week high. All 11 sectors ended higher...

The biggest winner in health stocks today was Hydrix (ASX:HYD) – up 9.68% off the back of news that Angel Medical Systems had completed its first commercial implantation in the US of the Guardian device – a cardiac detection monitor and pat...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Aussie shares rebounded today following rises in the US and Europe overnight, after having fallen for the previous two days. The ASX 200 regained 0.78%, with all 11 sectors in the green except for Industrials and IT. Healthcare and financia...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

ADELAIDE, Australia, July 6, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase 2b trial (the ATTUNE...

Summary The S&P/ASX200 traded up by 12.60 points or 0.17% at 7,327.60 by Tuesday afternoon. All the “big four” banks were trading higher ahead of the monetary policy announcement by the Reserve Bank. The energy sector was the best...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...